ALLSKIN | MED

Backed by science

Designed to work in partnership with clinical treatments

ALLSKIN | MED is a professional skincare range available exclusively in aesthetic skin clinics, combining patented, clinically-proven technologies and the most in-demand ingredients in dermatology. 

ALLSKIN | MED formulations are specifically designed to work in partnership with your clinical treatments, enhancing results and reducing downtime. The products are integrated into straightforward home-care regimes, allowing you to build tailored protocols for every skin type & indication. This holistic approach brings something different to your clinic, delivering transformative and long-lasting results to your patients.  

ALLSKIN | MED is shaped by science and backed by significant clinical data. It is developed by Cantabria Labs, international experts in dermatology and the geniuses behind Heliocare 360°, who are renowned for their commitment to research, patented technologies and high-quality ingredients. As a compact range of 18 products, ALLSKIN | MED complements any in-clinic offering, enhancing both the patient experience and results for specific indications. 

AESTHETICARE offers a closed-portal shop exclusively for ALLSKIN | MED where you can refer patients, generating additional revenue for your business and providing solutions for patients between clinic visits. 

Find out more at an introduction to ALLSKIN | MED meeting Register for meeting

Clinically-proven skincare range

Treatment enhancement

Every ALLSKIN | MED product and protocol is designed to work in synergy with aesthetic skin treatments. With ALLSKIN | MED, the skin is treated immediately post-procedure with SCA PRO Growth Factors, enhancing results and reducing downtime. The award winning SCA Pro Regenerating ampoules are clinically proven to enhance treatment results by up to 50% and can be used after any clinical treatment, including Ablative Co2 laser.

You can then provide your patients with a powerful ALLSKIN | MED Treatment Plan depending on their skin indications & goals to use at home to enhance and prolong results.

When using the ALLSKIN | MED post-procedure protocol & Treatment Plans alongside in-clinic treatments, you can expect:

  • A significant reduction in redness immediately after treatment1
  • Accelerated skin recovery2,3
  • Enhanced results for rejuvenating skin treatments2,3

Our Treatment Enhancement Range has been developed to cater to specific skin types and indications. The Plans focus around perfecting the complexion, improving skin firmness, boosting hydration, activating collagen production & reducing the risk of PIH.

The results your clients can expect from ALLSKIN | MED

After just 1 week’s use and no in clinic treatments

After just 1 week’s use and no in clinic treatments

After just 5 week’s use and no in clinic treatments

After just 5 week’s use and no in clinic treatments

What do ALLSKIN | MED clinics say?

I love ALLSKIN | MED for so many reasons – the regimes are straightforward, it’s a great price point and most of all, it works. The results we see from ALLSKIN | MED are amazing and our clients are always delighted. Eve Whiting, ALLSKIN | MED Specialist and Beauty Therapist at Suffolk Medical & Beauty Clinic

Partnerships

Become an ALLSKIN | MED partner clinic. We’ll work alongside you and your clinic, creating a strong and supportive partnership that’s bolstered by expert training and guidance. When you join us, you’ll receive more than just our products; you’ll get access to all the tools you need to deliver incredible client results and make your business a success. Your clients will also benefit from the ALLSKIN | MED closed online shop, where they can utilise your exclusive clinic code to shop the full range.

Marketing support

Our marketing campaigns are designed to raise brand awareness and generate new business for your clinic. Each campaign focuses on a specific product or skin indication, bolstered by inspiring merchandising, messaging and imagery. As an ALLSKIN | MED partner clinic, you will have exclusive access to the full marketing toolkit. What’s more, you’ll benefit from our ongoing press and social media campaigns, boosting brand awareness and driving new clients to your door.

Take a look at the latest ALLSKIN | MED partner campaign here.

Business support

ALLSKIN | MED partner clinics benefit from a dedicated Business Development Manager, who will be on hand to support you from the moment you launch the range in your clinic. With training sessions, educational support and an exciting marketing calendar, we are focused on making your business a success, keeping your team motivated and driving more retail sales. ​​

Masterclass education

As an ALLSKIN | MED partner clinic, you’ll be automatically enrolled in the AESTHETICARE Academy, which offers ongoing support and training. Take your knowledge to the next level and feel confident in upselling every product to your clients. Our masterclass presentations and partner sessions include all the information and materials you need for every ALLSKIN | MED campaign, including the science of each ingredient, different skin concerns and skincare routines. 

Find out more at an introduction to ALLSKIN | MED meeting with one of your fantastic Business Development Managers

Register for meeting

References
1 Sisto T, Bussoletti C, Celleno L. Half-face evaluation of regenerative and reparative properties of a serum containing the secret of Cryptomphalus aspersa 15% (SCA) versus placebo, in two groups of patients with acne and photoaging treated with chemical peeling. Esperienze dermatologiche-Dermatological experiences. 2013;15.
2 Truchuelo MT, et al. A cosmetic treatment based on the secretion of Cryptomphalus aspersa 40% improves the clinical results after the use of nonablative fractional laser in skin aging. J Cosmet Dermatol. 2020;19(3):622-8.
3 Fernandez-Gonzalez P, Vitale M, Truchuelo MT. Early and maintained application of the secretion of Cryptomphalus aspersa (SCA) 40% improves cutaneous healing after ablative fractional laser in skin aging. J. Cosmet. Dermatol. 2020;00:1–6.